Published in J Clin Oncol on May 09, 2016
Next-generation sequencing of tissue: A logical extension. Neurol Neuroimmunol Neuroinflamm (2016) 0.81
Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations. J Neurooncol (2017) 0.75
Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun (2017) 0.75
Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget (2016) 0.75
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. J Oncol (2017) 0.75
Non-blood circulating tumor DNA detection in cancer. Oncotarget (2017) 0.75
Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. Transl Res (2017) 0.75
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. Front Oncol (2017) 0.75
Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathol (2017) 0.75
Liquoral liquid biopsy in neoplastic meningitis enables molecular diagnosis and mutation tracking: a proof of concept. Neuro Oncol (2016) 0.75
An integrated map of genetic variation from 1,092 human genomes. Nature (2012) 59.82
A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet (2011) 59.36
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res (2010) 43.51
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform (2012) 23.58
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics (2009) 15.08
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res (2013) 6.10
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell (2009) 6.02
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med (2015) 5.03
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics (2012) 4.79
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (2013) 4.42
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. J Mol Diagn (2015) 3.84
Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol (2010) 3.51
Leptomeningeal metastases in the MRI era. Neurology (2010) 3.48
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med (2015) 3.33
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol (2006) 2.82
Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol (2014) 2.49
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol (2009) 2.33
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 2.12
The evolving war on cancer. Cell (2011) 2.02
Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med (2015) 2.01
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res (2010) 1.83
Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem (2014) 1.78
"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol (2011) 1.76
Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc (2014) 1.53
Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov (2015) 1.51
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids (2013) 1.40
Shifting paradigms: the seeds of oncogene addiction. Nat Med (2009) 1.37
Detection of cancer cells in the cerebrospinal fluid: current methods and future directions. Fluids Barriers CNS (2011) 1.32
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res (2015) 1.31
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol (2009) 1.30
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med (2013) 1.19
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest (2012) 1.16
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med (2015) 1.12
Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS Genet (2014) 1.09
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun (2015) 1.07
ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics (2014) 1.04
Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A (2015) 0.98
Brain tumor mutations detected in cerebral spinal fluid. Clin Chem (2015) 0.96
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet (2015) 0.95
Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat (2013) 0.90
High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs. Cancer Chemother Pharmacol (2015) 0.90
Detecting cancer by monitoring circulating tumor DNA. Nat Med (2014) 0.86
Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. Clin Chem (2000) 0.85
Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol (2011) 0.82
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev (2015) 0.82
PCR-detection of tumor-derived p53 DNA in cerebrospinal fluid. Am J Clin Pathol (1995) 0.79
Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here? Curr Oncol Rep (2015) 0.77